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Educational aims
●● To understand the different ways in which patients can contribute to clinical guidelines, research 
projects and educational activities.
●● To understand the barriers and potential solutions to these barriers from a physician’s perspective, 
in order to ensure meaningful patient involvement in clinical projects.
●● To understand the barriers and potential solutions from a patient’s perspective, in order to 
meaningfully involve patients in clinical projects.
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The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) is a European 
Respiratory Society (ERS) Clinical Research Collaboration dedicated to improving research and 
clinical care for people with bronchiectasis. EMBARC has created a European Bronchiectasis Registry, 
funded by the ERS and by the European Union (EU) Innovative Medicines Initiative Programme.
From the outset, EMBARC had the ambition to be a patient-focussed project. In contrast 
to many respiratory diseases, however, there are no specific patient charities or European 
patient organisations for patients with bronchiectasis and no existing infrastructure for patient 
engagement. This article describes the experience of EMBARC and the European Lung Foundation 
in establishing a patient advisory group and then engaging this group in European guidelines, an 
international registry and a series of research studies.
Patient involvement in research, clinical guidelines and educational activities is increasingly 
advocated and increasingly important. Genuine patient engagement can achieve a number of 
goals that are critical to the success of an EU project, including focussing activities on patient 
priorities, allowing patients to direct the clinical and research agenda, and dissemination of 
guidelines and research findings to patients and the general public. Here, we review lessons 
learned and provide guidance for future ERS task forces, EU-funded projects or clinical research 
collaborations that are considering patient involvement.
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Patients and carers are the key stakeholders in 
every aspect of medical care; yet, until recently, 
direct involvement of patients in clinical guidelines, 
clinical research studies or research consortia 
was uncommon [1]. Patients have typically been 
viewed as participants, e.g. subjects in a clinical 
trial, or involvement has been characterised as 
“tokenism” [1]. This is changing, as the value 
of patient involvement is being recognised, as 
physicians are being provided with the tools and 
guidance required to achieve meaningful patient 
engagement, and as research funders increasingly 
encourage or require patient involvement during the 
development of research projects [2–5].
The Value+ toolkit defines meaningful patient 
engagement as giving patients an active role in 
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activities or decisions that will have consequences 
for the patient community, because of their specific 
knowledge and relevant experience as patients [6].
Despite an increase in literature regarding patient 
involvement in projects, one of the major barriers 
to patient engagement is a lack of understanding 
from healthcare professionals about how to do it, 
and a lack of support in terms of funding for patient 
activities and tools and advice on how to do it [7–9]. 
From a patient’s perspective, while involvement in 
clinical projects can be a very positive experience, it 
is important to consider barriers, such as available 
time, self-confidence, stigma associated with illness 
and financial considerations, and to design patient 
involvement in a way that ensures that patients are 
adequately supported.
In this article, we describe a successful 
European Respiratory Society (ERS)/European 
Union (EU) project focussed on bronchiectasis, 
in which patients have been closely involved at 
every stage [10]. The purpose of this article is to 
highlight the multiple aspects of clinical guidelines 
and clinical research where patients can make a 
positive contribution, to highlight the lessons learnt 
from the European Multicentre Bronchiectasis Audit 
and Research Collaboration (EMBARC) project in 
terms of how to support patient engagement, and 
finally to reflect upon the patients’ experience of 
these projects, in order to help future patients and 
professionals to do better.
Patient involvement 
in EMBARC
EMBARC was one of the first ERS Clinical Research 
Collaborations awarded in 2013 [10, 11]. The 
specific objectives of EMBARC defined in its 
original constitution were: to create a European 
Bronchiectasis Registry to facilitate research 
and quality improvement initiatives across 
different healthcare systems; to build a network 
of researchers and experts in bronchiectasis to 
guide future research and clinical priorities; to 
attract new researchers and clinicians to the field 
of bronchiectasis; to support and encourage early 
career researchers in the field of bronchiectasis 
through involvement in network activities; and 
to build bronchiectasis research capacity in 
Europe [10].
Bronchiectasis is a poorly studied “orphan” 
condition with limited research and a poorly 
defined standard of care [12–14]. Patients often 
have poor quality of life, and may have poor 
experiences of healthcare due to delayed diagnosis, 
ineffective treatments, lack of understanding of 
their condition by the general public and by non-
specialist doctors, and a lack of access to quality 
information [15–18]. Therefore, a decision was 
made early in the EMBARC project to engage 
directly with patients to ensure that activities 
within the project were patient focussed and, 
where appropriate, patient led. EMBARC has been 
a multifaceted project with a range of different 
activities, all of which have involved patients. 
These are summarised in figure 1 and each is 
discussed in the following sections.
The European bronchiectasis 
patient advisory group
The formation of the European bronchiectasis 
patient advisory group was initially challenging, 
as in common with many rare or neglected 
conditions there is no formal patient organisation, 
charity or advocacy organisation for bronchiectasis. 
Identifying patients that can represent the broader 
patient community can therefore be difficult [13].
Hence, the proposed activities were 
dependent on the creation of a representative 
European patient group, which was facilitated 
by the European Lung Foundation (ELF). ELF 
was founded by the ERS in 2000 with the aim 
of bringing together patients and the public with 
respiratory professionals to positively influence 
lung health [19–22]. It has extensive experience 
of facilitating patient engagement with research 
and clinical projects, including in EU consortia 
such as the successful U-BIOPRED (Unbiased 
Biomarkers for the Prediction of Respiratory 
Disease Outcomes) project, and has published 
extensively on the topic [1, 19–25].
Using a combination of existing patient contacts, 
patients recruited from an online patient survey 
(discussed in a later section of this article) and 
patients recommended by European physicians, 
ELF developed an advisory group of >50 patients. 
Patients were supported by the patient projects 
co-ordinator at ELF and kept up to date with 
activities through regular newsletters.
As projects got underway, the patient advisory 
group members were asked to volunteer for activities 
that they would be interested in participating in. 
Patients were therefore able to choose a level of 
involvement that suited them, from being deeply 
involved in working groups to simply remaining up 
to date on activities and giving input by email.
Patient involvement in an 
ERS bronchiectasis guidelines 
task force
Patients, and particularly patients with bronchiectasis, 
have a strong motivation to ensure that they and 
other patients receive the best possible care. There 
is therefore a high level of interest among patients 
to become involved in guideline task forces. From 
the physician’s perspective, guideline development 
is substantially enhanced by patient involvement. 
ERS guidelines now use the GRADE (Grading of 
Recommendations Assessment, Development 
and Evaluation) approach for the development 
of evidence-based recommendations [26]. 
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GRADE encourages the incorporation of patients’ 
ideas, values and preferences at every stage of the 
guideline development process [26, 27].
For the 2017 ERS bronchiectasis guidelines, 
three patients were invited to participate as full 
members of the task force. This is, to the best of 
our knowledge, the first task force in which patients 
have been included as full voting members of the 
task force. Patients therefore played a full part in 
the development of the document, from the initial 
stages in which the most clinically important 
questions are determined using the PICO (patient, 
intervention, comparator, outcome) format, and 
particularly in rating the outcomes to be used in 
assessing treatments. In the GRADE approach, all 
possible outcomes are considered and are rated as 
critical, important or not/less important, with only 
critical or important outcomes being used to inform 
guideline recommendations [26, 27]. Patients are 
clearly in the strongest position to advise on what 
outcomes are important to them, and they greatly 
enhanced this evaluation process.
Patients attended every guideline meeting 
as full members, participating actively in the 
discussions and frequently being asked their views 
on different treatment approaches or proposed 
recommendations.
Guideline recommendations are formulated 
using evidence-to-decision frameworks in which 
evidence from clinical trials/observational studies 
is pooled and the data are then integrated with 
additional information, which includes the desirable 
and undesirable effects of a treatment, the certainty 
of evidence, resources, equity, acceptability and 
feasibility of the intervention [28]. Patients played 
a critical role in informing these assessments, by 
providing the guideline panel with information about 
how much or little they valued an intervention, the 
acceptability of different interventions to them 
and how they viewed the overall balance between 
desirable and undesirable effects [28].
Our experience was that the patients’ perspective 
often differed from those of guideline panellists and 
that patients made an important contribution in 
modifying the ultimate guideline recommendations.
Patients were asked to review the final guideline 
document and, at the time of writing this article, 
a lay version of the guideline designed for patients 
and the wider public is being prepared by the patient 
advisory group in collaboration with ELF.
Patient involvement in the 
European Bronchiectasis Registry
The formation of the EMBARC registry was a major 
undertaking, involving over 150 centres in more 
than 40 countries. As bronchiectasis is a poorly 
researched disease, there have been limited 
epidemiological data and we know very little about 
the natural history [29–31]. The initial development 
of the registry required the development of a case 
ERS Bronchiectasis Guidelines
Patient activities
  · 3 patients embedded as full task force   
    members
  · Development of PICO questions and grading of 
    outcomes from the patient perspective
  · Key role in evidence-to-decision framework
  · Patients’ ideas, values and preferences 
    incorporated into each recommendation
  · Patient summary of guideline 
    recommendations prepared and
    disseminated
European Bronchiectasis Registry
Patient activities
  · Defining research priorities and objectives     
    through a multinational patient survey
  · Review and amendment of the case report form
  · Key role for patients in developing governance   
    structure and data access policy
  · Patient representatives on the steering
    committee, informing all major network
    decisions
Physician and patient education
Patient activities
  · Need assessment: defining patient and 
    physician education needs as part of a 
    multidisciplinary working group
  · Content review: ensuring content is patient 
    focussed and recommendations reflect 
    patients’ ideas, values and preferences
  · Patients closely involved in development of the  
    World Bronchiectasis Conference: sessions 
    opened and closed by patient speakers
Clinical trials
Patient activities
  · Trial priorities determined by patient 
    priority-setting exercise
  · Patient involvement in reviewing protocols and 
    grant applications for network trials
  · Protocols and proposals amended based on 
    patient feedback
  · Patient member of iABC consortium ethics 
    board
  · Patient review of study documents and 
    involvement in dissemination
Figure 1 Summary of patient involvement in the EMBARC project.
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report form and a governance structure that would 
allow the registry to succeed over the long term. 
This, in turn, needed to be focussed on the outputs 
that we wished to achieve through the research. To 
inform this, we conducted an online patient survey 
co-ordinated by ELF. The survey was sent to over 
100 European physicians caring for bronchiectasis 
patients, and the online survey was ultimately 
completed by more than 1000 patients and carers 
of those with bronchiectasis, with 711 included in 
the final analysis [11]. The questions asked in this 
survey were developed by a small working group 
composed of three physicians, representatives of 
ELF and four patients [11].
The result has been published as a research 
priorities document in the European Respiratory 
Journal and this “research roadmap” defined by 
patients and physicians is now used as the basis 
for the EMBARC strategy and analysis plan [11].
The case report form of the registry was 
developed with input from patients and directed 
by the results of the patient survey. The study 
documents, such as the patient information sheet 
and consent form, were also reviewed and amended 
by patients [10].
The governance structure of the registry included 
patients, and patients have attended each of the 
registry steering committee meetings. The patient 
representatives also gave a closing address at the 
general assembly of the EMBARC project in 2015, 
and an opening address at the EMBARC general 
assembly in 2016 (figure 2).
Patients have a stake in ensuring that their data 
are used to benefit the whole research community 
and, ultimately, other patients. The patient advisory 
group therefore played a key role in EMBARC 
adopting a very open and transparent data access 
process, which allows any research with a legitimate 
scientific question to access the data [32].
The EMBARC registry is ongoing and patients 
continue to play a key role in its governance and 
development as they have done since its inception.
Patient involvement in 
bronchiectasis clinical trials and 
studies
One of the key objectives of the registry is to make 
it easier for academic researchers, consortia and 
industry to conduct clinical research studies and 
clinical trials. Since its inception, the EMBARC 
project has supported more than 10 such 
studies, ranging from multinational clinical 
trials to observational surveys [33–39]. For grant 
applications, patients have provided input into study 
design and advice about patient involvement, and 
have reviewed dissemination plans. Patients have 
written letters of support to encourage funders to 
support bronchiectasis-related projects. Patients 
are now serving on advisory boards and the ethical 
committees of trial programmes, including the 
inhaled antibiotics in bronchiectasis and cystic 
fibrosis (iABC) consortium funded by the EU 
Innovative Medicines Initiative, of which EMBARC 
is a member [40]. Patients have had a strong impact 
on the studies performed. As an example, patient 
representatives felt strongly that comorbidities 
were not sufficiently addressed in the work of the 
registry or in clinical guidelines, feeding back to the 
working group that often comorbidities associated 
with bronchiectasis were the factors most strongly 
influencing their quality of life. EMBARC undertook 
a linked registry study around comorbidities that 
confirmed the patients’ impression, leading to a 
high impact publication in The Lancet Respiratory 
Medicine [34]. This is a clear example of how 
patients can drive the research agenda. As these 
clinical trials continue, patients will be involved in 
trial conduct and the dissemination of results.
Patient involvement in 
education initiatives, the ERS 
Annual Congress and World 
Bronchiectasis Conference
There is a significant need for physician education 
in bronchiectasis, as highlighted by the patient 
priorities survey, in which one of the top patient 
priorities was that their primary care physician 
should have greater knowledge and understanding 
of their condition [11]. Patients have been integral to 
the development of a physician education platform 
that is due for launch in 2017. In addition, patients 
consistently report a lack of high-quality educational 
material available for them to understand their 
own condition. Patients have therefore led the 
development of a patient education website to be 
launched by ELF in 2017 to provide high-quality 
ERS Bronchiectasis Guidelines
Figure 2 A group of bronchiectasis patients address the EMBARC annual meeting.
Breathe | September 2017 | Volume 13 | No 3 199
Patient participation in ERS projects
peer-reviewed information about bronchiectasis 
targeted at the general public. These initiatives have 
been conducted under the same principles as the 
task force, with multidisciplinary working groups 
that include patients as equal partners. Patients 
also participated in the first World Bronchiectasis 
Conference, held in Hannover, Germany, in 2016. 
The conference was opened by a lecture by Marta 
Almagro, a patient with bronchiectasis who gave a 
powerful, personal presentation about the impact 
of the disease and the importance of encouraging 
greater awareness of bronchiectasis (figure 3). 
Patients have also attended EMBARC meetings at 
the past three ERS International Congresses.
Experience of patient 
involvement: the clinician’s 
perspective
In part as a result of the strong support from 
patients, the EMBARC project has been a major 
success. The European Bronchiectasis Registry is 
now well established with >8000 patients enrolled 
at the time of writing, and the project has produced 
a large number of important publications. Although 
the benefit of patient involvement is clear from the 
information presented here, the process presented 
many challenges.
The EMBARC study team had limited prior 
experience of patient involvement in research 
projects or guidelines. There was no established 
pathway or guidelines for how patients should be 
involved in research or task forces, and as a result 
the “rules of engagement” had to be generated 
by EMBARC and ELF on a bespoke basis to suit 
the project. There was some initial resistance to 
patient involvement from some quarters, because 
of concerns that patients may be upset by some 
aspects of discussion or that the presence of 
patients may stifle debate. As an example, if 
a member of a guideline task force is receiving 
a drug that the guideline task force wants to 
recommend is ineffective or potentially harmful, 
how would that patient react, and would this harm 
their relationship with their existing healthcare 
professional?
Additional barriers include the need for 
in-depth scientific discussion, which may not 
always be accessible for patients or carers, leading 
to the concern that discussions may be stifled if 
conversations are constantly being interrupted 
for lay explanations. Table 1 outlines some of 
the barriers and concerns and how these were 
addressed in this project. These can be used as a 
framework for future projects of this kind, while 
recognising that barriers may be different depending 
on the nature of the projects being proposed.
Physician attitudes towards patient involvement 
have clearly changed over the course of the project, 
with these concerns addressed. Clinicians and 
allied health professionals have commented how 
overwhelmingly positive the experience of patient 
involvement has been, and the genuine level of 
enthusiasm this has generated is reflected in 
increasing requests to involve patients in further 
events, committees and activities. Nevertheless, 
EMBARC has made plenty of mistakes along the way 
and it is hoped that the guidance in this document 
can help to highlight both the good and bad practices 
we have identified over the past 3 years so that 
future projects can learn from our experience.
Experience of patient 
involvement: the patient’s 
perspective
Patients become involved in research and guideline 
projects for a variety of reasons, including their 
own personal experiences of care and a desire to 
improve treatment for themselves and for others 
with a similar condition. Making a decision to 
become involved in a project like EMBARC is a major 
undertaking and there are a few things that can 
be done to make it easier for patients to volunteer 
to become involved [41]. The EMBARC patients’ 
key recommendations for patient involvement in 
research are presented in table 2.
We recommend that clinicians explain very 
clearly what they expect from patients, which may 
be helped by generating a job description for patient 
representatives. It is important to make clear at the 
beginning what time commitment is needed and 
also to let patients know if any training is required or 
will be provided. We recommend involving patients 
ERS Bronchiectasis Guidelines
Figure 3 Marta Almagro opens the first World 
Bronchiectasis Conference.
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Table 1 Recommendations for clinicians, written by both physicians and patients, to ensure appropriate patient engagement
Barriers Recommendations
Representativeness 
(i.e. are patients 
involved in 
the project 
representative of 
the overall patient 
population?)
Involve more than one patient in any project. This has multiple benefits, including increasing the 
representativeness, but also allowing for peer support and ensuring there is representation if patients 
become unwell and are unable to attend meetings or participate in activities. If patients are attending 
as representatives of a large patient group or organisation, ensure that discussions or outcomes are also 
shared with the wider group so that a larger body of patients has the opportunity to contribute.
Ensure patient representatives understand that they are representing other patients and not just giving 
their personal story.
Incorporate broader patient data into data collection, e.g. by performing a literature review for patient 
perspective articles or performing a patient survey with a sufficient sample size to be considered 
representative of wider patient opinion. Patient representatives can advise on the most relevant patient-
centred search terms of literature reviews and ELF can also provide advice on this.
Language Currently, there is a requirement for participating patients to speak English. This can result in a UK/Ireland 
bias and so it is important to try to achieve representation of other European countries. Where activities 
can be multilingual (such as patient surveys), these methods should be used. ELF provides support for 
multilingual focus groups and surveys.
Patient travel and 
reimbursement
Face-to-face meetings are the most effective way to engage patients. The cost of this is the requirement 
for patients to travel to meetings, which is expensive and time consuming. It is essential that the project 
funds patient travel adequately and in an appropriate way and timeline. Where travel is prevented 
through ill health or other issues, teleconference facilities should be offered to avoid excluding patients’ 
valuable contributions.
The INVOLVE guidelines (www.invo.org.uk) from the National Institute for Health Research (UK) suggest that, 
wherever possible, patients involved in research projects should receive payment or a fee for participation. 
However, they note that consideration should be given to whether payments may affect state benefits.
Lack of scientific 
knowledge or 
background
Patients cannot be expected to be experts in clinical trial design, observational research or guideline 
methodology. In the ideal scenario, patients would be trained with the knowledge that they require, 
through schemes such as the European Patient Ambassador Programme (EPAP; www.epaponline.org). If 
it is not feasible for patients to have such training, we recommend:
1) Project chairs meet with patients prior to meetings so that patients can have an explanation of the 
context of the expected discussion;
2) Use of natural breaks in discussion to explain to patients in lay terms what is being discussed and ask 
patients specific questions where their input is needed;
3) Debriefing with patients after meetings to ensure they have understood the discussions.
For rare diseases, including rare pulmonary diseases, EURORDIS (Rare Diseases Europe) provides training 
to empower patient representatives to participate in clinical research and other clinical projects.
Perception of 
“tokenism”
Set specific objectives for patient involvement in projects and communicate these to all stakeholders. The 
professional participants in a task force or research project should understand what the role of patients 
in the project is, and patients should understand exactly what is expected of them.
Involve patients as equals. We have had a very positive experience of including patients as full equal 
members of a guideline task force.
Patients isolated 
or ignored in 
meetings
There is a responsibility on the chairs of meetings to prompt participants to involve the patient 
representatives, and to prompt patients to provide input where appropriate. Patient participation can be 
facilitated by making clear the role of patients to both the patients and physicians at the start of the project.
Smaller group work, such as subcommittees or working groups, can make it easier for patients to 
participate as groups are smaller, but there is similarly a responsibility on subgroup participants to ensure 
patients are involved.
Patients lacking 
confidence to get 
involved
Welcome and introduce patients at the start of every meeting. Encourage all task force or study team 
members to introduce themselves; even if all of the professionals are well known to each other, they are 
not well known to the patients. Chairs should give an introduction explaining the role of the patients and 
encouraging task force or study members to involve the patients.
It is particularly helpful for patients to meet with the chairs or ELF representatives prior to meetings (and 
particularly the first meeting) so that they know what to expect and get to know some other people in the 
meeting prior to joining larger group meetings.
Research or guideline meetings often also involve social events and it is appropriate to involve patients in 
social events so that they can get to know panel members in a more relaxed setting and are not excluded.
Continued
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at an early stage, when they have the opportunity 
to actively influence the research, rather than 
later on when most of the major decisions have 
been made. It is also important to make sure that 
patients know who to contact with questions or 
for information.
As a result of an open set of medical 
professionals, the patients’ input and concerns 
are fully reflected in all aspects of the EMBARC 
project. A prime example was in agreeing the final 
draft of the guidelines, where patient acceptability 
is one of the criteria. At this stage, the healthcare 
professionals actively sought the input of the 
patient representatives. The recommendations in 
the 2017 ERS bronchiectasis guidelines have all 
been developed with patients and a lay version of 
the guidelines will published alongside the main 
document. Another important impact patients 
made was to request that all publications arising 
from EMBARC should be freely available to patients, 
with the effect that all publications from EMBARC 
have been open access since 2015.
At the start of the patient involvement, however, 
meetings were difficult and there was a need 
for clear guidance on the potential role(s) of the 
patient (from observer to full participant) and 
how the meetings could be structured to reflect 
the presence of patients. To many patients, these 
meetings present a challenge on five fronts: 1) it 
is a formal meeting and many patients may not 
attend formal meetings of any type in their day to 
day life; 2) the group of medical professionals are 
already known to each other but not to the patient; 
3) the medical members may also be treating the 
patient away from the meeting; 4) the potential 
for “deep” scientific and medical discussion with 
associated jargon; and 5) the need to address topics 
such as life expectancy calculations, which can be 
upsetting to patients.
The biggest challenge for a patient is the first 
meeting. This was also highlighted from the 
clinicians’ perspective in terms of resistance from 
the clinicians, which may result from meeting a 
patient out of the context of a clinic visit, or from 
the instant access of the patient to a club that the 
clinicians have invested many years to gain entry 
into. In most cases it was clear that this was the 
clinician’s first experience of involving patients in 
research and clinical projects.
Each patient will be different in their experience 
of meetings, their subject matter knowledge, 
how outgoing they are, and their financial 
circumstance. An underestimated impact of 
involvement in research projects is the impact 
that medical data can have on patients. For 
example, several patients involved in the EMBARC 
project are chronically infected with Pseudomonas 
aeruginosa. Across multiple discussions in both 
research and guideline meetings, it became clear 
that the physicians regard P. aeruginosa as a poor 
Table 1 Continued
Conflicts of interest 
and confidentiality
Just like physicians, patients may have conflicts of interest that are relevant to their participation in task 
forces and research projects.
Project chairs should give consideration to how they will manage patients’ conflicts of interest. This 
may include financial conflicts of interest (patients with business interests related to the healthcare 
field or having relationships with pharmaceutical companies) or non-financial conflicts of interest. 
The most frequent non-financial conflict of interest is that the patient may be a patient under the care 
of a member of the task force. This is not necessarily a problem, but consideration should be given to 
whether patients may feel coerced to participate, and whether they may feel able to give their honest 
opinion, which may be at odds with the opinion of their physician.
Patient confidentiality should be maintained at all times. Patients may choose to share information about 
their medical background, but their physician should not disclose information to the panel or panel 
members without patient consent.
Lack of awareness 
of governance and 
regulatory aspects 
around patient 
involvement
Clinicians may be concerned about involving patients in research in the belief that all work with patients 
requires ethical or other governance approvals. Note that ethical approval is not required to involve 
members of the public in designing or conducting research studies, participating as a member of an 
advisory group or helping to develop study materials or questionnaires.
Identifying suitable 
patients
Consider the knowledge and experiences you need to inform the project. Try to create a “job description” 
or specification of the kind of patient you wish to involve.
Involve patient organisations wherever possible as they provide peer support, training and, in some cases, 
resources to aid patients. Involving patient organisations also generally means the representatives can be 
the collective voice of a group rather than simply representing themselves.
Consider the commitment required by patients. It is important to remember that patients have jobs, lives 
and commitments of their own and may not be able to attend all meetings or respond to short deadlines. 
Give information about the time commitment and project duration up front to let patients make an 
informed decision about whether to participate.
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prognostic sign, a sign of increased mortality 
and more rapid disease progression requiring 
more intensive treatment [38, 39, 42]. Hearing 
this can be very upsetting for a patient who 
knows that they are infected with P. aeruginosa 
but who may not have been previously made 
aware of its health consequences. The “clinical” 
tone of these discussions was described by 
one patient as “brutal”. This is not a scenario 
unique to bronchiectasis, as the reaction would 
no doubt be similar for a patient with lung 
cancer on hearing lung cancer 5-year mortality 
Table 2 EMBARC patients’ key recommendations for patient involvement in research
Do Don’t
Involvement •	 Involve patients at an early stage
•	 Involve patient organisations and more than 
one patient
•	Ensure patients are able to really influence 
the work
•	Ask patient opinions once decisions are 
already made
•	Assume that individual patients are 
representative of a wider patient population
•	Exclude patients from key meetings/
decisions
Preparation and training •	Make sure patients know what is expected 
from them
•	Be clear about time commitment required 
and project duration
•	Provide formal training if needed
•	Consider in advance what to do if patients 
become ill
•	Discuss with patients beforehand if the 
project is likely to touch on sensitive 
or potentially upsetting issues such as 
mortality rates, serious complications or the 
effectiveness/ineffectiveness of treatments
•	Give patients insufficient notice of meetings 
or deadlines for feedback
•	Expect patients to have any special 
knowledge or skills; training should be 
provided if these are required
•	Allow the day of the meeting to be the first 
occasion the chairs meet or speak with the 
patients
•	Discuss patients’ confidential medical 
information either pre-meeting or during 
meetings
Meetings •	Consider meeting venues that are accessible 
to patients
•	Organise meeting venues that are easy 
to get to (e.g. parking, disabled access). 
Consider mid-morning or afternoon 
meetings to allow for travelling time
•	Offer a pre-meeting telephone call or 
discussion to prepare patients
•	 Introduce everyone, ensure patients are 
involved
•	Avoid jargon and ensure the chairs confirm 
patient understanding regularly
•	Take frequent breaks
•	Allow discussion of potentially upsetting or 
distressing topics without first preparing 
patients
•	Conduct long meetings without breaks or 
refreshments
•	Use jargon, technical language or complex 
diagrams/slides where these can be avoided
•	Exclude patients from discussions or prevent 
them from contributing
Finance •	Ensure expenses are reimbursed fully and 
promptly so that patients are not left “out of 
pocket” for long
•	Rely on patients to know how to access 
reimbursement systems
•	 Leave patients “out of pocket” for long 
periods
Publication and 
dissemination
•	Ensure patients are involved in publications 
if they have contributed and meet the 
criteria for authorship
•	Consider lay versions of important 
documents
•	Consider making articles open access so that 
patients can read them for free
•	Assume that patients do not want to be 
involved in publications
•	 Fail to acknowledge patient involvement in 
journal articles
•	 Leave key articles behind a paywall so that 
patients cannot access them
Communication •	Ensure patients have a point of contact who 
is accessible and responsive
•	Ensure patients receive feedback on how 
their involvement is affecting the project(s)
•	Dismiss any problems or concerns identified 
by patients
•	Expect patients to respond to short deadlines 
or undertake large tasks
•	Assume patients know who they can talk to 
for advice or to express concerns
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rates, or a patient with sleep apnoea learning 
about their cardiovascular risks, if they are not 
warned beforehand that such information will 
be discussed [43, 44]. It is important to inform 
patients that aggregated research data show 
effects across large populations, and do not 
necessarily have implications for them personally. 
It is important to emphasise that all patients are 
different and have different needs for treatment. 
To give another example, physicians will often 
discuss that a therapy “has no evidence to support 
it” or “does not work” when the patients attending 
the meeting are receiving that therapy. The 
patient’s natural reaction is to question whether 
they should be taking the therapy, and whether 
their doctor may have made a wrong decision in 
prescribing it. One patient in the bronchiectasis 
guidelines task force was receiving a therapy that 
the panel determined should not be used due to 
an increase in side-effects in clinical trials. After 
discussion, it was very clear that the patient had 
benefited from this treatment. It is important to 
understand that research and guideline projects 
look at the balance of risks and benefits across 
a population, and do not determine whether an 
individual patient will benefit from a treatment. 
This distinction is not immediately obvious unless 
clearly explained to patients. Patients told us that 
they would prefer to have a single point of contact 
with whom they can discuss issues as they arise, 
and from whom they can obtain information. This 
can be a member of the panel, or someone from 
a patient organisation such as ELF.
The European Lung 
Foundation perspective
ELF was founded by the ERS to bring together 
patients and the public with respiratory 
professionals to positively influence lung health. 
ELF encourages healthcare professionals to 
engage with patients and patient organisation 
representatives to ensure that patient perspectives 
are at the centre of their project set-up, decision 
making and outcomes.
Over the last 5 years, ELF’s remit has expanded 
significantly as its role has become better known 
within the ERS, resulting in an increasing number 
of ERS project chairs engaging with ELF for support 
in facilitating patient input into their activities. This 
has resulted in a steep learning curve for ELF and, 
with increasing experience in this area, and building 
on the facilitation of patient input into over 15 ERS 
task forces and projects to date, means that we 
are continually looking to review and refine our 
approach.
Our experience of working with EMBARC, which 
has been a very successful collaboration, forms the 
basis for the challenges and learning points we have 
identified for this article and which are outlined in 
table 3. Many of the recommendations and do’s and 
don’ts outlined in table 2 also give us an opportunity 
to improve our ways of working to ensure smoother 
participation and involvement for patients in the 
future. Some of the challenges identified here have 
been responded to already and solutions have been 
implemented.
Table 3 shows the key challenges we faced 
specifically in working with EMBARC on their 
multiple projects and we have illustrated the 
Educational questions
1. Which of the following statements regarding patient involvement in 
research projects is not correct?
a) The Value+ toolkit defines meaningful patient engagement as 
giving patients an active role in activities or decisions that will have 
consequences for the patient community, because of their specific 
knowledge and relevant experience as patients
b) ELF can connect researchers with patients and patient 
organisations in order to facilitate patient involvement in research
c) It is important to involve patients in research projects at an early 
stage, ideally at the pre-application stage for grant applications or 
in the development of protocols
d) It is highly recommended to involve multiple patients or patient 
organisations in order to have a broad patient view
e) Patients providing input into clinical trials must participate in 
and receive training from the European Patient Ambassador 
Programme (EPAP)
2. Which of the following statements regarding dissemination of 
research findings are correct, where studies are conducted in 
collaboration with patients?
a) Scientific reports are generally poorly accessible for patients and so 
it is advisable to produce lay versions of published studies
b) It is advisable to make published research papers open access 
where possible, so that they are accessible to patients and patient 
groups as well as the wider public
c) Scientific journals usually produce lay versions or short summaries 
of their articles, so there is no requirement for authors to do so
d) Patients are typically not interested in participating in manuscript 
publications
e) ELF facilitates patient involvement in research projects but does not 
publish manuscripts or get involved in the publication process
3. Which of the following statements is true regarding patient 
involvement in ERS task forces and guidelines?
a) It is mandatory to include patients as part of the task force
b) It is a requirement of the GRADE methodology used to generate 
ERS guidelines that the patient perspective is taken into account 
when forming recommendations
c) Patients do not have to declare conflicts of interest as members of 
task force panels
d) Patients cannot meet the ICMJE (International Committee of 
Medical Journal Editors) criteria for authorship and should not be 
included as authors in a task force document/clinical guideline
e) Patients’ ideas and preferences should take priority over clinical 
evidence when forming guideline recommendations
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Table 3 Challenges and solutions from a European Lung Foundation perspective
Project area Specific challenge Solutions implemented Future recommendations
Engagement with 
and management of 
expectations, project 
chairs and members
ELF to maintain an overview of 
multiple project actions and 
deadlines to ensure patient 
input co-ordinated effectively 
and with feasible deadlines.
Open and regular communication 
between EMBARC, ELF and 
patient representatives.
Shared commitment and 
enthusiasm by all to ensure 
positive engagement of, and 
experience for, patients involved 
in the projects.
ELF inclusion in development 
of project action plans at 
earliest stage possible.
Recruitment of a patient 
advisory group
Larger than usual response 
to our invitation for 
patients to get involved in 
EMBARC projects resulted 
in >50 members on our 
bronchiectasis patient 
advisory group (rather than 
∼6–12).
Defined the >50 members as 
a “patient reference panel” 
for wider consultation at key 
points during projects. From 
this panel, we engaged with 
those individuals who wanted 
to be more involved in working 
groups.
Potential model for future 
projects. Benefits of having 
the wider reference panel:
1) There is a core base of 
people ready and engaged 
for consultation at key 
points;
2) Opportunities for 
easier recruitment for 
future projects or if 
representatives have to 
drop out due to ill health or 
other commitments;
3) Wider promotion of project 
outcomes through the 
core group.
Communication and 
consultation with wider 
patient advisory group
Ensuring two-way 
communication between 
patient representatives 
attending task force meetings 
and wider patient advisory 
panel to ensure that wider 
views are represented.
Development of “Conflict of 
Interest and Confidentiality” 
form for patient representatives 
and patient advisory group 
members to complete prior to 
involvement in task forces and 
projects.
Provide clearer guidance and 
mechanisms for patient 
representatives to easily 
give feedback and gather 
views from the wider patient 
advisory group.
Preparation and 
training for patient 
representatives 
involved in task forces
Lack of detailed, written 
guidance for patient 
representatives involved in 
task force meetings.
Developed guidance booklet 
including case study from 
patient representative involved 
in this task force.
Review guidance and training 
in light of recommendations 
raised in this article.
Ongoing support for 
patient representatives
Increasing demands on core 
group of patients as workload 
increases.
Ongoing communication with 
patient representatives and 
project chairs throughout the 
project to highlight potential 
pressure points.
Setting realistic role 
descriptions, expectations 
and timelines from the 
beginning and reviewing 
these throughout the 
project.
Guidance for task force/
project chairs
No defined process. Clarification of our patient input 
process to aid discussions 
and planning (supplementary 
material).
Basic guidance for task force 
chairs developed.
Involve patient 
representatives at initial 
discussion stage to ensure 
best patient involvement 
approaches are used.
Review current guidance for 
task force chairs, to expand 
and include a checklist of 
key responsibilities.
Include recommendations 
for keeping ELF involved 
and up to date in project 
development and timeline.
Continued
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solutions that have already been implemented 
in response to these, as well as future 
recommendations.
One of the solutions we have been able to put in 
place over the life of the task force project has been 
to refine our patient input process, which is used as 
the basis for initial discussions with project leaders 
and chairs to define the appropriate elements of 
patient involvement to include within each project. 
We continually review our approach and ways of 
working to ensure that we can build on feedback 
received and adapt where necessary to ensure 
quality patient input.
Conclusions
Patient involvement in the design, conduct, 
implementation and dissemination of clinical 
research and clinical guidelines can greatly enhance 
the quality and impact of such projects. Here we 
have described the lessons learned, mistakes made 
and recommendations for the future developed as 
a result of the extensive public involvement in the 
EMBARC project. We hope such information will 
be of use to researchers planning similar projects 
in future.
Suggested answers
1. e) Patients providing input into clinical trials may benefit from 
participating in the EPAP programme, but this is not mandatory. If 
patients have no training in clinical trial methodology it is advisable for 
the chairs of the research project to meet with participants and explain 
in detail what is expected of the patients, and provide information to 
patients regarding the technical aspects of trial design and conduct.
2. a) and b) Lay versions of published articles are highly recommended 
and patients can assist with developing these. Open access publishing 
allows patients to access the original published article. Scientific 
journals generally do not produce lay versions and so this is something 
that should be produced by authors or patient organisations. Patients 
should be given the opportunity to be authors if they meet the criteria 
for authorship. ELF has extensive experience of publishing.
3. b) The GRADE methodology includes patients’ ideas and preferences 
as a core part of the evaluation of interventions. It is not mandatory to 
include patients in guidelines task forces, but it is recommended for the 
majority of task forces. Patients can have conflicts of interest and these 
should be declared to the panel where patients participate as members 
of the panel. Patients can meet the criteria for authorship and should 
be included if they meet these criteria. Patients’ ideas and preferences 
are important, but will not usually take priority over clinical evidence 
formed from systematic literature review in making recommendations.
Table 3 Continued
Face-to-face meetings 
with patient 
representatives
Value of face-to-face meetings 
recognised but posed some 
difficulties for individual 
patients around potential 
risks; also some technology 
difficulties encountered.
Developed risk protocol 
document in response to this 
for use with patients attending 
face-to-face meetings in future.
Ongoing use and review of 
risk protocol.
Evaluation of patient 
involvement in projects
Lack of embedded evaluation 
processes.
Added a question to task force 
annual review reports about 
their experience of patient 
involvement to date, to help 
capture feedback part-way 
through the project so can tackle 
any issues raised.
Piloted an evaluation survey for 
patient advisory group members 
at end of project (aim to widen 
this out to other projects).
Reflection and production of the 
content for this article.
Develop ELF evaluation 
strategy to identify best ways 
of capturing experiences of 
patient involvement, in order 
to promote high-quality 
engagement in the future.
Suggest involvement of 
patients and healthcare 
professionals in evaluation 
stages.
Ongoing informal and open 
communication with 
patient representatives to 
encourage the raising of any 
issues/problems that can be 
addressed.
Ending a project How to acknowledge patient 
participation at the end of 
projects.
Not yet applicable. Define process for exit 
strategy for patient 
representatives when 
projects end.
Current exploration of 
maintaining patient advisory 
groups over longer term.
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